BCL-6 Positive on ReceptivaDx? What to Do Next
Your BCL-6 came back positive — what should you actually do next?
A positive BCL-6 result is worth taking seriously, but the evidence behind it has shifted — recent, larger studies haven't consistently replicated the dramatic outcome differences from earlier research. It shouldn't be treated as a solo verdict that mandates laparoscopy; weigh it alongside your symptoms, treatment history, and imaging findings with your RE.
If you've just gotten a positive BCL-6 result from ReceptivaDx testing, you're likely standing at a real decision point: pursue a laparoscopy to look for and treat endometriosis, or move forward with treatment as-is. This is one of the harder calls in fertility care to make well, partly because the evidence behind BCL-6 itself has genuinely shifted over the past few years — and a lot of what's readily available online hasn't caught up with that shift. Here's an honest, current picture.
What BCL-6 Is Actually Testing For
BCL-6 is a protein measured via endometrial biopsy, originally identified in cancer research before being studied as a marker of endometrial inflammation. The biological rationale is genuinely reasonable: BCL-6 has been linked to progesterone resistance in the endometrium — meaning the tissue doesn't respond normally to progesterone's signal to prepare for implantation — and this progesterone resistance is mechanistically connected to endometriosis-associated inflammation. Elevated BCL-6 has also been shown in research to correlate with a high positive predictive value for surgically confirmed endometriosis in certain infertility populations. The logic connecting BCL-6, endometriosis, and implantation difficulty is not invented — it has real biological grounding.
The Original, Promising Data
Early studies presented compelling numbers. Foundational research reported that patients testing BCL-6 negative had substantially better subsequent IVF outcomes than those testing positive — differences reported in some of this early data were stark, with negative-testing patients showing dramatically higher pregnancy and live birth rates than positive-testing patients in their next transfer attempt. This is the data that established ReceptivaDx as a widely used tool and shaped the expectation that a positive result meaningfully predicts poor outcomes, while treatment (ranging from letrozole to laparoscopic excision) could meaningfully change that trajectory.
Why the Picture Has Gotten More Complicated
More recent, larger, and more rigorously controlled studies have not consistently replicated those early findings, and this matters a great deal for a decision this consequential. A 2022 study published in Fertility and Sterility, looking at a general normal-responder IVF population rather than a population specifically selected for suspected endometriosis, found no significant difference in live birth rates between patients with elevated versus normal BCL6 expression — concluding that routine BCL6 screening before a first embryo transfer had limited utility for predicting IVF outcomes in a general infertility population. A separate study specifically examining patients with recurrent pregnancy loss or recurrent implantation failure found no significant difference in implantation, miscarriage, or ongoing pregnancy rates between BCL6-positive patients who were treated and those who weren't — a finding the authors described as raising real concern that a single biomarker may not reliably guide treatment decisions on its own.
There are also meaningful methodological complications. BCL-6 expression levels appear to vary depending on how the endometrial sample was prepared — levels measured in progesterone-exposed endometrium differ from those in natural-cycle samples, which raises real questions about comparing results across different studies and protocols. BCL-6 positivity also doesn't consistently align with other endometrial receptivity testing frameworks (like ERA testing), suggesting it may be capturing a specific inflammatory or progesterone-resistance phenotype rather than functioning as a universal, standalone marker of implantation readiness.
A 2022 Fertility and Sterility editorial addressing this directly — titled, fittingly, "Predicting implantation failure: to BCL6 or not to BCL6" — captures where the field actually stands: genuinely unresolved, with BCL6 potentially useful as one marker of endometriosis-associated inflammation, but not established as a reliable, standalone predictor that should drive treatment decisions on its own.
So What Should Actually Inform Your Decision?
Given this evidence picture, a positive BCL-6 result is reasonable to take seriously, but it shouldn't be treated as a solitary, definitive verdict that automatically mandates laparoscopy. What's worth weighing alongside it:
Your symptom picture. Do you have pelvic pain, painful periods, painful sex, or other classic endometriosis symptoms independent of the BCL-6 result? A positive result alongside a strong symptomatic picture carries more weight than a positive result in someone with no other endometriosis indicators. We work through exactly this in PCOS & Endometriosis.
Your treatment history. Have you had prior failed transfers, particularly with euploid (chromosomally normal) embryos, where implantation failure itself is the unexplained factor needing an explanation? BCL-6 positivity is more clinically relevant as one piece of an unexplained recurrent implantation failure picture than as a routine, first-line screen. More on that here: does acupuncture for endometriosis fertility help.
Imaging and prior findings. Has anything on ultrasound or prior surgical history suggested endometriosis independent of this test? Corroborating evidence matters more than a single biomarker in isolation.
What "either way" support looks like. Regardless of whether you pursue laparoscopy, addressing the broader inflammatory and hormonal environment — including progesterone resistance mechanisms, systemic inflammation, and immune regulation — is reasonable supportive work that doesn't require surgery to begin, and isn't wasted effort even if you do ultimately pursue a laparoscopic evaluation. Related reading: the 90-day window after excision surgery.
The Bottom Line
A positive BCL-6 result — something we talk through often with patients from across Long Island — deserves a real conversation with your RE about your full clinical picture, not a decision made from the test result alone. The evidence has moved from "this predicts outcomes reliably" toward "this may identify a relevant inflammatory phenotype in select patients, but isn't validated as a universal, standalone predictor" - and that shift matters enormously for how much weight a single positive result should carry in a decision as significant as whether to pursue surgery.
This article is for general educational purposes and isn't a substitute for individualized guidance from your reproductive endocrinologist. The decision to pursue laparoscopic evaluation should be made directly with your care team, weighing your full clinical picture.
East to West Fertility, is a metabolic and immune-focused fertility practice in Huntington, NY, serving Long Island, NYC, and beyond. We support the inflammatory and hormonal environment relevant to implantation, working alongside your REI regardless of which path you choose after a BCL-6 result. Learn more about our Metabolic & Immune Fertility Evaluation at easttowestfertility.com or call 631-416-4940.
References:
"Predicting implantation failure: to BCL6 or not to BCL6." Fertility and Sterility editorial, 2022.
Klimczak AM, Herlihy NS, Scott CS, et al. "B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population." Fertility and Sterility, 2022.
"Endometrial BCL6 Expression and Reproductive Outcomes in Infertile Women: A Systematic Review." 2026.
"A single biomarker may not yield a reliable binary clinical answer: B cell lymphoma 6 testing and resulting interventions for endometriosis in infertility care." F&S Reports, 2025.
